+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 50Years - 85Years
All Genders
ID07557121

Evaluating Safety and Vision Outcomes of AIV007 Periocular Injection Compared to Eylea in Neovascular Age-Related Macular Degeneration Patients

Led by AiViva BioPharma, Inc. · Updated on 2026-11-04

35

Participants Needed

2

Research Sites

7 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying whether AIV007, given as a periocular injection, benefits patients with neovascular wet age-related macular degeneration by improving vision and maintaining safety. This phase 2 trial compares AIV007 with the standard treatment Eylea, focusing on visual acuity, retinal thickness, and the duration of treatment effect over several months. The study aims to answer key questions about safety, vision improvement, and how long AIV007s effects last. Participants are randomly assigned to receive either AIV007 at doses of 6 or 8 mg or the standard Eylea injection. In the first 6 months, treatments are given in a masked fashion with monthly clinic visits for safety checks and vision assessments. Eligible participants may receive a second open-label injection of AIV007 to evaluate repeat dosing effects. During the study, participants return monthly for vision testing, eye imaging, and safety monitoring. Researchers measure best-corrected visual acuity at 6 months and assess the durability of treatment effects at 5 months. The study includes detailed eye exams and monitors for any adverse effects. Participation lasts up to the study completion in August 2027, with ongoing observation of vision and safety.

CONDITIONS

Brief Title

Safety and Efficacy of AIV007 Periocular Injection in Patients With Neovascular Age-Related Macular Degeneration

Research Team

D

Darlene C. Deecher, phd

D

Diane DS Tang-Liu, PHD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here